A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)
Running, not enrolling · Phase 3
Conditions studied: Spinal Muscular Atrophy
In brief
In this study, researchers will learn more about the use of a higher dose of nusinersen (BIIB058) in participants with spinal muscular atrophy (SMA). This study will focus on teenagers and adults who are unable to walk on their own and who have previously taken another drug for SMA called risdiplam. The main goal of this study is to learn about the effect of high dose (HD) nusinersen on muscle and movement ability (motor function) in SMA. The main question that researchers want to answer is: \- How do the scores of a movement test called the Revised Upper Limb Module change from the start of treatment? The Revised Upper Limb Module is a test used to measure a participant's ability to do specific tasks that involve their shoulders, arms, wrist, elbows, and hands. It measures the changes in their abilities over time. Researchers will also learn more about the safety of HD nusinersen. They will check participants for adverse events and changes in vital signs, heart tests, and laboratory tests including blood and urine tests. The study will be done as follows: * Participants will be screened to check if they can join the study. * After screening, participants will enter the Core Treatment period. * At the start of the Core Treatment period, they will receive 2 "loading" doses of nusinersen. These are 50 mg doses of nusinersen given 2 weeks apart. * Afterwards, they will continue to receive "maintenance" doses of nusinersen once every 4 months. These doses will be 28 mg. * The Core Treatment period will last about 2 years, with a follow-up visit 4 months after the last dose. * Participants who complete the Core Treatment period will have the option to continue receiving 28 mg of nusinersen in the Long-Term Extension (LTE) period for about 2 years. There will also be a follow-up visit 4 months after the last dose. * Nusinersen will be given through a lumbar puncture, which involves injecting the drug into the fluid around the spinal cord in the lower back. * In total, participants will have up to 18 study visits. They will also be called by researchers after each dose of nusinersen. * Participants will stay in the study for about 4.5 years if they complete both the Core Treatment and LTE periods.
Key facts
- Study ID
- NCT05067790
- Run by
- Biogen
- People needed
- 45
- Starts
- 2022-01-21
- Expected to finish
- 2027-09-24
- Last updated by the study team
- 2026-05-22
Who can join
Age: 15 and older, up to 50. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Barrow Neurological Institute — Phoenix, Arizona, United States
- Stanford Neuroscience Health Center — Palo Alto, California, United States
- Rare Disease Research, LLC — Atlanta, Georgia, United States
- Boston Children's Hospital — Boston, Massachusetts, United States
- Memorial Healthcare — Owosso, Michigan, United States
- Columbia University — New York, New York, United States
- Wake Forest University - School of Medicine - Central — Winston-Salem, North Carolina, United States
- University of Pennsylvania — Philadelphia, Pennsylvania, United States
- Neurology Rare Disease Center — Denton, Texas, United States
- The University of Texas Health Science Center at Houston — Houston, Texas, United States
- University of Washington Medical Center — Seattle, Washington, United States
- Universitaetsklinikum Heidelberg — Heidelberg, Baden-Wurttemberg, Germany
- Universitaetsklinikum Ulm — Ulm, Baden-Wurttemberg, Germany
- Klinikum rechts der Isar der TU Muenchen — Munich, Bavaria, Germany
- Universitaetsklinikum Essen — Essen, North Rhine-Westphalia, Germany
- Semmelweis Egyetem — Budapest, Hungary
- Fondazione IRCCS Istituto Neurologico Carlo Besta — Milan, Italy
- Fondazione Serena Onlus - Centro Clinico Nemo — Milan, Italy
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS — Roma, Italy
- Ospedale S G Battista Molinette — Torino, Italy
- Yokohama City University Hospital — Yokohama, Kanagawa, Japan
- NHO Osaka Toneyama Medical Center — Toyonaka-shi, Osaka, Japan
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.